Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues $ 5,231,000 $ 2,954,000
Cost of Revenues 1,386,000 884,000
Gross Profit 3,845,000 2,070,000
Operating Expenses    
Research and development 4,085,000 2,708,000
Sales and marketing 2,276,000 1,639,000
General and administrative 6,105,000 9,171,000
Acquisition-related costs 121,000 470,000
Amortization of intangibles 1,322,000 502,000
Total Operating Expenses 13,909,000 14,490,000
Loss from Operations (10,064,000) (12,420,000)
Other Income (Expense)    
Interest income (expense), net 2,000 (349,000)
Loss on exchange of debt for equity 0 (30,000)
Provision for valuation allowance for held for sale loan 0 (117,000)
Other income 108,000 386,000
Unrealized loss on equity securities (1,503,000) 0
Total Other Income (Expense) (1,393,000) (110,000)
Net Loss, before tax (11,457,000) (12,530,000)
Income tax provision (100,000) (9,000)
Net Loss (11,557,000) (12,539,000)
Net (Loss) Income Attributable to Non-controlling Interest (346,000) 18,000
Net Loss Attributable to Common Stockholders (11,211,000) (12,557,000)
Deemed dividend for the modification related to Series 8 Preferred Stock (2,600,000)  
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock 1,500,000  
Net loss attributable to common stockholders, basic (17,362,000) (12,557,000)
Net loss attributable to common stockholders, diluted $ (17,362,000) $ (12,557,000)
Net Income (Loss) Per Share    
Net Loss Per Share - Basic (in usd per share) $ (0.13) $ (0.16)
Net Loss Per Share - Diluted (in usd per share) $ (0.13) $ (0.16)
Weighted Average Shares Outstanding    
Basic (in shares) 138,502,493 78,942,697
Diluted (in shares) 138,502,493 78,942,697
Series 7 Convertible Preferred Stock    
Other Income (Expense)    
Accretion of Preferred Stock $ (4,555,000) $ 0
Series 8 Convertible Preferred Stock    
Other Income (Expense)    
Accretion of Preferred Stock (548,000) 0
Deemed dividend for the modification related to Series 8 Preferred Stock (2,627,000) 0
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock 1,469,000 0
Amortization premium- modification related to Series 8 Preferred Stock $ 110,000 $ 0